Alzamend Neuro Inc
ALZN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.74M
Close$
$0.02
98.1% downside
Current Fair Value
98.1% downsideOvervalued by 98.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.74 Million |
|---|---|
| Enterprise Value | $1.02 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-11.32 |
| Beta | 0.11 |
| Outstanding Shares | 3,804,741 |
Return
| Return on Equity | -322.36% |
|---|---|
| Return on Assets | -174.22% |
| Return on Invested Capital | -323.30% |
Valuation & Multiples
| P/E Ratio | -0.64 |
|---|---|
| PEG | -0.58 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 11, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 1, 2026
EPS Estimate
$-0.67
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.04%▼ 3.42% |
|---|---|
| Total Invested | $122,410▼ 72.63% |
| Investors Holding | 12▼ 1.00% |
ESG Score
No data
About Alzamend Neuro Inc
3 employees